Here's Why Biotech Deals Are All the Rage Right Now

In this video from Motley Fool Live, recorded on Nov. 30, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss recent licensing and acquisition that large drugmakers have undertaken. Biogen (NASDAQ: BIIB) made a investment in the development of a pair of drugs from Sage Therapeutics (NASDAQ: SAGE). Eli Lily (NYSE: LLY) took a more muted approach toward its licensing deal with Precision BioSciences (NASDAQ: DTIL).